Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO

Rhea-AI Summary

Mirati Therapeutics, Inc. (MRTX) announced a late-breaking presentation at the ESMO IO Annual Congress on December 7, 2022, detailing results of the combination treatment using adagrasib and pembrolizumab for advanced non-small cell lung cancer with a KRAS^G12C mutation. The oral presentation is scheduled from 2:15 p.m. to 2:25 p.m. CET. Following the session, a Virtual Investor Event will occur at 5:00 p.m. CET, accessible via webcast. For more details, visit Mirati.com.

SAN DIEGO, Nov. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS^G12C mutation. Findings will be presented on December 7 at the 2022 European Society of Medical Oncology Immuno-Oncology (ESMO IO) Annual Congress as an oral presentation from 2:15 p.m.-2:25 p.m. CET / 8:15 a.m.-8:25 a.m. ET (Presentation #LBA4) during the "Proffered Paper session 1" session of the congress.

Mirati Therapeutics will host a Virtual Investor Event following the session on Wednesday, December 7, 2022 at 5:00 p.m. CET / 11:00 a.m. ET / 8:00 a.m. PT.

Investors and the general public are invited to access the live webcast of the presentation at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-254-3590, confirmation code: 1294615. A replay of the presentation will be available approximately 2 hours after the event has ended at the same website.

About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. is a biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet medical need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook.  

Forward Looking Statements

This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati"). Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati's drug development pipeline, including without limitation adagrasib (selective KRAS^G12C inhibitor), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRAS^G12D inhibitor), is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the "SEC") available at the SEC's Internet site (www.sec.gov). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. 

Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-late-breaking-combination-results-and-host-virtual-investor-relations-event-at-esmo-io-301686583.html

SOURCE Mirati Therapeutics, Inc.

FAQ

What are the key findings of Mirati Therapeutics' presentation on December 7, 2022?

Mirati will present results of the combination treatment of adagrasib and pembrolizumab for advanced non-small cell lung cancer with a KRAS^G12C mutation.

When is the Mirati Therapeutics virtual investor event scheduled?

The virtual investor event will take place on December 7, 2022, at 5:00 p.m. CET.

How can I access the presentation by Mirati Therapeutics at ESMO IO?

The presentation can be accessed via live webcast on Mirati's website under the Investors and Media section.

What is the significance of the adagrasib and pembrolizumab combination treatment?

This combination aims to provide a new treatment option for patients with advanced non-small cell lung cancer harboring the KRAS^G12C mutation.

Where can I find more information about Mirati Therapeutics?

For more information, visit Mirati's website at Mirati.com.